Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 1996-2002

  Clairmont, Caroline ^a,d   Lee, K C ^a   Pike, J ^a   Ittensohn, M ^a   Low, K B ^a   Pawelek, J ^a   Bermudes, D ^a   Brecher, S M ^c   Margitich, D ^b   Turnier, J ^b   Li, Z ^a   Luo, X ^a   King, I ^a   Zheng, L M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oread Inc   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANCER INHIBITION; GENE DELETION; GENETIC MANIPULATION; GENETIC STABILITY; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TISSUE DISTRIBUTION; VIRUS ATTENUATION; VIRUS SHEDDING;

ANIMALS; ANTINEOPLASTIC AGENTS; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; SALMONELLA TYPHIMURIUM; TISSUE DISTRIBUTION;

EID: 0034088909     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315497     Document Type: Article

References (32)

1. 1. Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light of modern research. Cancer Res 1946; 6:205-16.
2. 2. Beg AA, Baltimore D. An essential role for NF-/κB in preventing TNF-α-induced cell death. Science 1996; 274:782-4.
3. 3. Graham FO, Coleman PN. Infection of a secondary carcinoma by Salmonella Montevideo. Br Med J 1952; 1:1116.
4. 4. Giel CP. Abscess formation in pheochromocytoma. N Engl J Med 1954; 251: 980-2.
5. 5. Gill GV, Holden A. A malignant pleural effusion infected with Salmonella enteritidis. Thorax 1996; 51:104-5.
6. 6. Carey RW, Holland JF, Whang HY, Neter E, Bryant B. Clostridial oncolysis in man. Eur J Cancer 1967; 3:37-46.
7. 7. Herr HW. Tumour progression and survival in patients with t1g3 bladder tumours: 15-year outcome. Br J Urol 1997; 80:762-5.
8. 8. Jackson AM, Ivshina AV, Senko O, et al. Prognosis of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 1998; 159:1054-63.
9. 9. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57:4537-44.
10. 10. Hardt WD, Urlaub H, Galan JE. A substrate of the centisome 63 type III protein secretion system of Salmonella typhimurium is encoded by a cryptic bacteriophage. Proc Natl Acad Sci USA 1998; 95:2574-9.
11. 11. Chen LM, Kaniga K, Galan JE. Salmonella spp. are cytotoxic for cultured macrophage. Mol Microbiol 1996; 21:1101-15.
12. 12. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-70.
13. 13. Karow M, Georgopolous C. Isolation and characterization of the Escherichia coli msbB gene, a multicopy suppressor of null mutations in the high-temperature requirement gene htrB. J Bacteriol 1992; 174:702-10.
14. 14. Khan SA, Everest P, Servos S, Foxwell N, Zahringer U, Brade H. A lethal role for lipid A in Salmonella infections. Mol Microbiol 1998; 29:571-9.
15. 15. Clementz T, Zhou Z, Raetz CRH. Function of the Etcherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A. J Biol Chem 1997; 272:10353-60.
16. 16. Somerville JE, Cassaiano L Jr, Bainbridge B, Cunningham MD, Darveau RP. A novel Escherichia coli lipid A mutant that produces an anti-inflammatory lipopolysaccharide. J Clin Invest 1996; 97:359-65.
17. 17. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17:37-41.
18. 18. Low KB, Ittensohn M, Lin S, et al. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors [abstract 581]. Proc Am Assoc Cancer Res 1999; 40:87.
19. 19. Bochner BR, Huang H-C, Schieven GL, Ames BN. Positive selection for loss of tetracycline resistance. J Bacteriol 1980; 143:926-33.
20. 20. National Committee for Clinical Laboratory Standards. Methods for determination of anti-microbial susceptibility tests for bacteria that grow aerobically: approved standard M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
21. 21. National Committee for Clinical Laboratory Standards. Methods for determining bacteriocidal activity of anti-microbial agents. Document M26-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.
22. 22. National Committee for Clinical Laboratory Standards. M100-S8 performance standards for antimicrobial susceptibility testing. 8th informational supplement. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.
23. 23. Zheng LM, Ojcius DM, Garaud F, et al. Interleukin 10 inhibits tumor metastases through an NK cell dependent mechanism. J Exp Med 1996; 184: 579-84.
24. 24. Bousquet PF, Brana MF, Conlon D, et al. Clinical evaluation of LU 79553: a novel bis-naphthalimide with potent anti-tumor activity. Cancer Res 1995; 55:1176-80.
25. 25. Liu M, Bryant MS, Chen J, et al. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother Pharmacol 1999; 43:50-58.
26. 26. Takasaka M, Kohno A, Sakakibara I, Narita H, Honjo S. An outbreak of salmonellosis in newly imported cynomolgus monkeys. Jpn J Mod Sci Biol 1988; 41:1-13.
27. 27. Tribe GW, Fleming MP. Biphasic enteritis in imported cynomolgus (Macaca fascicularis) monkeys infected with Shigella, Salmonella, and Campylobacter species. Lab Anim 1983; 17:65-69.
28. 28. Clairmont C, Lee K, Ittensohn M, et al. Pre-clinical toxicology of VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors [abstract 2552]. Proc Am Assoc Cancer Res 1999; 40:385.
29. 29. Lee KC, Zheng L-M, Luo X, et al. Comparative evaluation of the acute toxic effects in monkeys, pigs and mice of a genetically engineered Salmonella strain (VNP20009) being developed as an antitumor agent. Int J Toxicol 2000; 19:1-7.
30. 30. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of fas ligand (CD95L). Science 1998; 282:1714-17.
31. 31. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991; 60:85-100.
32. 32. Luo X, Ittensohn M, Low B, et al. Genetically modified Salmonella typhimurium inhibited growth of primary tumors and metastases [abstract]. Am Assoc Cancer Res 1999; 40:476.